MX2016015484A - Inhibidores del factor xia. - Google Patents

Inhibidores del factor xia.

Info

Publication number
MX2016015484A
MX2016015484A MX2016015484A MX2016015484A MX2016015484A MX 2016015484 A MX2016015484 A MX 2016015484A MX 2016015484 A MX2016015484 A MX 2016015484A MX 2016015484 A MX2016015484 A MX 2016015484A MX 2016015484 A MX2016015484 A MX 2016015484A
Authority
MX
Mexico
Prior art keywords
factor xia
compounds
xia inhibitors
inhibitors
formula
Prior art date
Application number
MX2016015484A
Other languages
English (en)
Spanish (es)
Inventor
Zhuyan Guo
Scott D Edmondson
Rongze Kuang
Amjad Ali
Linda L Brockunier
So Sung-Sau
Heping Wu
Wanying Sun
Mertz Eric
Liu Weiguo
K Ogawa Anthony
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016015484A publication Critical patent/MX2016015484A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2016015484A 2014-05-28 2015-05-22 Inhibidores del factor xia. MX2016015484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462003693P 2014-05-28 2014-05-28
PCT/US2015/032091 WO2015183709A1 (en) 2014-05-28 2015-05-22 Factor xia inhibitors

Publications (1)

Publication Number Publication Date
MX2016015484A true MX2016015484A (es) 2017-03-23

Family

ID=54699606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015484A MX2016015484A (es) 2014-05-28 2015-05-22 Inhibidores del factor xia.

Country Status (10)

Country Link
US (1) US9783530B2 (enExample)
EP (1) EP3148542B1 (enExample)
JP (1) JP2017517512A (enExample)
KR (1) KR20170005871A (enExample)
CN (1) CN106413710A (enExample)
AU (1) AU2015267305A1 (enExample)
CA (1) CA2947987A1 (enExample)
MX (1) MX2016015484A (enExample)
RU (1) RU2016150410A (enExample)
WO (1) WO2015183709A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物
NO2760821T3 (enExample) 2014-01-31 2018-03-10
EP3180325B1 (en) * 2014-07-28 2019-03-20 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
MX2017009445A (es) 2015-01-20 2017-11-08 Merck Sharp & Dohme Inhibidores del factor xia.
US10472344B2 (en) 2015-12-02 2019-11-12 Merck Sharp & Dohme Corp. Factor XIa inhibitors
WO2018039094A1 (en) 2016-08-22 2018-03-01 Merck Sharp & Dohme Corp. Pyridine-1-oxide derivatives and their use as factor xia inhibitors
CN111763171B (zh) * 2019-04-02 2023-12-22 上海美悦生物科技发展有限公司 一种FXIa凝血因子抑制剂及其药物组合物、制备方法和医药用途
MX2022003649A (es) * 2019-09-27 2022-06-08 Shenzhen Salubris Pharm Co Ltd Inhibidores del fxia y metodo de preparacion de los mismos y uso farmaceutico de los mismos.
WO2022057849A1 (zh) * 2020-09-17 2022-03-24 浙江海正药业股份有限公司 哌嗪类衍生物及其制备方法和用途
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006115652A1 (en) 2005-04-20 2006-11-02 Janssen Pharmaceutica, N.V. Fluorinated pyridine n-oxide thrombin modulators and process for n-oxidation of nitrogen containing heteroaryls
JP2009519966A (ja) * 2005-12-14 2009-05-21 ブリストル−マイヤーズ スクイブ カンパニー セリンプロテアーゼ阻害剤として有用な6員ヘテロ環
WO2007109459A2 (en) * 2006-03-21 2007-09-27 Janssen Pharmaceutica, Nv Pyridines and pyridine n-oxides as modulators of thrombin
AU2008266228A1 (en) * 2007-06-13 2008-12-24 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
EP2729150B1 (en) * 2011-07-08 2016-09-14 Merck Sharp & Dohme Corp. Factor ixa inhibitors
US10011585B2 (en) 2014-07-28 2018-07-03 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US9868727B2 (en) 2014-07-28 2018-01-16 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3180325B1 (en) 2014-07-28 2019-03-20 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS

Also Published As

Publication number Publication date
JP2017517512A (ja) 2017-06-29
CN106413710A (zh) 2017-02-15
EP3148542A4 (en) 2018-01-03
WO2015183709A1 (en) 2015-12-03
EP3148542B1 (en) 2019-02-27
US20170197953A1 (en) 2017-07-13
US9783530B2 (en) 2017-10-10
KR20170005871A (ko) 2017-01-16
AU2015267305A1 (en) 2016-11-03
EP3148542A1 (en) 2017-04-05
CA2947987A1 (en) 2015-12-03
RU2016150410A3 (enExample) 2018-11-30
RU2016150410A (ru) 2018-06-28

Similar Documents

Publication Publication Date Title
MX2016015484A (es) Inhibidores del factor xia.
MX387515B (es) Inhibidores de factor xia.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
GEAP202014670A (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2017009445A (es) Inhibidores del factor xia.
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
TN2018000229A1 (en) Pyrimidinones as factor xia inhibitors
MX2018002217A (es) Nuevos compuestos biciclicos como inhibidores de autotaxina (atx).
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2016011556A (es) Composiciones que comprenden un agente amargante.
SG11201703988PA (en) N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors,
EA201791133A1 (ru) Ингибиторы erk
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
PH12017501523A1 (en) Selective bace1 inhibitors
MX2016011558A (es) Composiciones que comprenden un agente amargante.
TW201613892A (en) Forms and compositions of an ERK inhibitor
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
PH12017501879A1 (en) Methods for treating cancer
PH12017501864A1 (en) Compositions and methods for treating autism
MX2017003138A (es) Compuestos de azetidiniloxifenilpirrolidina.
PH12017501880A1 (en) Methods for treating cancer